Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 19Neoplasm Metastasis 6Brain Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Malignant Female Reproductive System Neoplasm 1Hemangiosarcoma 1HER2-positive Breast Cancer 1HER2 Positive Breast Carcinoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Lobular 1Carcinoma 1

Interventions

Carboplatin 4Trastuzumab 3Cyclophosphamide 3Paclitaxel 2Letrozole 2Fulvestrant 2Docetaxel 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1entrectinib 1Vorinostat 1Vinorelbine 1Thiotepa 1Taxes 1Tamoxifen 1Sugars 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Naltrexone 1Melphalan 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Liquid Biopsy 1High-Energy Shock Waves 1Goserelin 1Fluorine-18 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Lobular × neratinib × Clear all
NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
30 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡